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INTRODUCTION
By late April, more than 80% of the world’s 
COVID-19 vaccines had gone to people in 
wealthy countries, with just 0.3% to people 
in low- income countries.1 This reprehen-
sible imbalance is no accident. High- income 
countries have used neocolonial negotiating 
power, global policy leverage and capital to 
procure enough doses to cover 245% of their 
citizens while leaving few doses for poorer 
countries.2 As a result, lower- income coun-
tries may not be able to vaccinate their popu-
lations until 2023.3
Such inequity is yet another example of 
how the interests of racial capitalism run 
roughshod over the golden rule of global 
solidarity—attend to the highest risk first.4 
Currently, older and medically vulnerable 
individuals are dying from COVID-19 dispro-
portionately in poor countries, while young, 
healthy individuals are getting vaccinated 
in wealthy ones.5 Vaccine apartheid is a not 
novel phenomenon. The notion that only 
certain corners of the world get to benefit 
from life- saving treatments is an everyday 
reality of a global health system driven by 
a capitalist, philanthropic model.6 7 But in 
times of crises—and as new variants threaten 
the vaccination plans of wealthy countries—
these inequities and their solutions come to 
the forefront of global debate.8
Policy- makers in rich nations are aware 
of these issues. But the solutions they have 
proposed so far do nothing to address the 
underlying structural problems. They offer 
charitable donations and partial, tempo-
rary fixes that are designed to deflect the 
substantive demands for reform that global 
South countries are fighting for, including 
challenges to unethical intellectual property 
(IP) regimes.9 This approach will not work, 
because it is not designed to ‘work.’ If we want 
to end vaccine apartheid, we need to target 
the root causes of global health inequities. We 
need reparative justice.
THREE LIMITED ‘SOLUTIONS’ TO VACCINE 
INEQUITY
There are currently three approaches to 
reduce inequity in COVID-19 vaccine distri-
bution: bilateral charity, multilateral charity 
and temporary waivers or suspensions of IP.
The first is the most straightforward. 
States that stockpile COVID-19 vaccines have 
committed to sharing their leftovers with 
low- income and middle- income countries. 
Norway was one of the first nations to accede 
to donating doses to poorer countries in 
parallel with its vaccine programme.10 This is 
the weakest form of equity as it is unclear if 
this will be done for free, at a lower cost, tied 
to diplomacy or conditionality, or crucially, 
when these vaccines will be made available, 
where they will go, or how many will be deliv-
ered. The bilateral charity approach has little 
to do with equity and more to do with geopol-
itics, wealth and aid dependency.11 12
The second is multilateral charity, best 
exemplified by COVAX. In 2020, COVAX 
emerged as an international collaboration 
by the World Health Organisation (WHO), 
United Nations Children’s Fund, Gavi and 
the Coalition for Epidemic Preparedness 
Innovations to ensure equitable global access 
to COVID-19 vaccines.13 Rich countries can 
access doses for 10%–50% of their popula-
tions, depending on how much they have 
paid in, and poor countries can access doses 
for 20% through the scheme. It is the 20% for 
poor countries that has come to be COVAX’s 
unique selling point: here is a mechanism that 
ensures every country in the world can get the 
vaccine regardless of ability to pay. This is the 
first time such an initiative has been trialled.
The shortcomings of COVAX are numerous. 
If vaccines are delivered as planned, COVAX 
may reach 27% of the population in lower- 
income countries by the end of 2021—a 
depressing goal compared with the estimated 
70% coverage needed for herd immunity and 
the open vaccine access currently granted to 
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Americans.14 15 Furthermore, COVAX is still significantly 
underfunded and there are concerns regarding supply 
chains.
While capital and resource transfer from wealthy 
countries to poorer ones is surely needed in the current 
pandemic response, any system that solely relies on aid 
will ultimately fail to achieve equity. In the setting of 
vaccine scarcity, in which suppliers are unable to deliver 
doses as scheduled and countries are banning exports 
to keep vaccines at home, there is a risk that COVAX 
aid- recipient states will fall further down the priority 
list, awaiting the leftover vaccines from the rich country 
stockpiles.16–18
What may be most pernicious about the COVAX 
scheme, however, is that rich countries and their phar-
maceutical companies have repeatedly used it as a shield 
to deflect demands for IP waivers. This is an enduring 
problem with aid: it papers over and distracts our atten-
tion away from the underlying structural violence. And 
in so doing, it maintains and perpetuates inequalities. 
Over 50 years ago, Kwame Nkrumah observed how aid 
is a ‘revolving credit’ which returns to countries of the 
global North in the form of increased profits.19 To the 
extent that COVAX is being leveraged to protect corpo-
rate patents and profits, Nkrumah’s words continue to be 
germane.
The third approach is focused on pooling, temporary 
waivers, or suspension of IP. In May 2020, the WHO 
created the COVID-19 Technology Access Pool for 
companies to share IP and transfer technologies in a 
coordinated manner. But to date, not a single company 
has utilised the transfer process—likely because such 
forms of global IP sharing would quell profits, even if 
royalties are included.20 Pharmaceutical companies 
and universities prefer one- off transfer deals because it 
enables them to set their own terms with non- disclosure 
agreements. Given that they are accountable to share-
holders and boards—not patients—financial incentives 
will drive transfer decisions, not public health demand.
Following the blockages at the WHO around IP, 
attention shifted towards the World Trade Organisa-
tion (WTO). In October 2020, India and South Africa 
proposed a temporary waiver of IP rights to COVID-19 
technologies for the duration of the pandemic, so that 
all manufacturers with sufficient capacity and shared 
know- how could start production.21 Although backed by 
over 100 countries within the WTO and a global campaign 
for the ‘People’s Vaccine,’ the proposal has been repeat-
edly blocked at every committee meeting since then by 
select wealthy countries with large pharmaceutical indus-
tries, including the UK, Japan and EU states.22 23
Those who oppose the IP waiver argue that it will not 
do anything to solve the problem: even if you were to 
liberate the recipe for the vaccines, low- income and 
middle- income countries do not have the capacity to 
produce it.24 But this argument is specious. For one, 
several middle- income countries—including India, 
Brazil, Senegal and South Africa—do have the ability 
to ramp up production by repurposing existing manu-
facturing capacity.25 In addition, an IP waiver can and 
should be supplemented with technology transfers, logis-
tical support and financial investment to facilitate this 
repurposing process. And the most important point is 
that such a waiver could drastically reduce costs across 
the board, making vaccine imports more affordable for 
poor countries.
Opponents of the waiver also claim that IP- related 
obstacles can be addressed through existing arrange-
ments for ‘compulsory licensing’ under the WTO’s 
Agreement on Trade- Related Aspects of Intellectual 
Property Rights (TRIPS).26 But the past evidence suggests 
that this process is slow, cumbersome and subject to 
various shaming practices by the international commu-
nity.27 28 Some point instead to the possibility of volun-
tary licensing. But voluntary licenses are often executed 
secretly and are limited to companies or governments 
that can afford them. The University of Pennsylvania, 
which owns IP rights relating to the mRNA vaccines, is 
helping Chulalongkorn University in Bangkok develop a 
vaccine production facility. This partnership was possible 
because Thailand—unlike other middle- income coun-
tries—was able to put up the money.29 Poorer countries 
are left out. Sharing of IP and technology transfers can 
and will accelerate global vaccine production. The ques-
tion is on whose terms. Organisations such as the WHO 
and African Union are currently mobilising support and 
resources to accelerate production in low- income and 
middle- income countries.30 31 But these efforts will be 
to waste unless IP for COVID-19 technologies is shared 
broadly and quickly.
VACCINE COLONIALITY
Donor- based approaches to vaccine equity are grounded 
in old, even colonial ideas of aid and dependency, which 
have failed to serve the health needs of the Majority 
World or deliver on health equity. This failed model has 
not promoted health equity in the past and is clearly 
inadequate in the present, on account of dependency on 
donor whims (the bilateral ‘leftovers’ approach), persis-
tent funding gaps and shortfalls (COVAX), and time- 
consuming diplomacy and filibustering over what is or is 
it not within current trade rules (WTO).
Once again in the political economy of global health, 
the charitable model of COVAX becomes the smoke-
screen for inequitable systems. When states are asked 
about their stockpiling, they point to COVAX. When 
pharmaceutical companies are asked about IP, they point 
to COVAX or their low- cost commitment. The focus on a 
donor- based model of aid in achieving vaccine equity has 
distracted leaders from the ideologies, economic systems 
and trade regulations that leave access to medicine to 
the forces of the marketplace rather than global health 
priorities.32 Achieving global vaccine justice requires a 
rapid shift in trade regulations and contract transparency 
that streamlines IP sharing and technology transfers. 
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The resultant collaborations across economies will not 
only accelerate vaccine production but will also increase 
competition and push vaccine prices down.
Finally, old models of vaccine equity have not kept 
pace with changes in discourse and thinking around 
global health governance, equity and justice. 2021 is 
not the early 2000s, where new public–private partner-
ships or funding models were de rigueur. Donor countries 
are increasingly wary of aid dependency as they pay the 
cost of continuing high profile health programmes with 
diminishing strategic returns. Aid- recipient countries are 
similarly exasperated by funding gaps that lead to delays 
and materiel shortfalls, the NGO- industrial complex and 
attendant consultants that rationalise them, and funda-
mentally, by the notion that their populations only seem 
to matter when another state can capitalise on them.
CONCLUSION
Vaccine apartheid is only one symptom of broader global 
health inequalities that have their roots in colonialism 
and persist today because of neocolonial forms of power. 
As Grosfoguel writes, ‘The heterogeneous and multiple 
global structures put in place over a period of 450 years 
did not evaporate with the juridical–political decolo-
nisation of the periphery over the past 50 years. We 
continue to live under the same ‘colonial power matrix.’ 
With juridical–political decolonisation we moved from a 
period of ‘global colonialism’ to the current period of 
‘global coloniality.’33
Vaccine justice starts with moving beyond aid models 
of vaccine donation, in which poorer countries are gifted 
vaccine leftovers. It demands rapidly achieving global 
consensus for the IP waiver, democratising vaccine IP 
and know- how and supporting low- income and middle- 
income countries to build manufacturing capacity for 
this pandemic and the next. These steps can mark the 
start of a reparative justice movement in global health 
that demands we confront and overturn colonial legacies 
that continue to devastate the health of low- and middle- 
income countries.34 A commitment to funding vaccine 
justice in the face of the COVID-19 pandemic can be a 
first step in this direction.
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